MedTrace Logo

An Adequate Cost Effective Follow Up Protocol For Bone and Soft Tissue Sarcomas

NCT05827458 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2023-04-25

No results posted yet for this study

Summary

Bone and soft tissue sarcomas are rare tumors, accounting for approximately 1% of all adult malignancies. The majority of bone and soft tissue sarcomas occur in the extremities. After treatment of the primary tumor, 40 % to 60% of the patients will develop local or distant recurrent disease. The ultimate determinant of survival in patients with bone and soft tissue sarcomas is the development of distant metastasis. Modern multimodality therapy has improved patient survival; hence follow-up surveillance strategies are becoming increasingly important with significant clinical and fiscal implications. However, the ideal postoperative protocol vis a vis frequency and appropriate screening modalities for these uncommon neoplasms remains ill-defined. Although guidelines have been proposed for follow-up of patients , there is a paucity of data in medical literature on the effectiveness of these recommendations. A prospective randomized controlled trial to evaluate the effectiveness of follow up strategies in picking up disease recurrence and their role in influencing overall survival would go a long way in answering some of these questions.

Conditions

  • Sarcomas

Sponsors & Collaborators

  • Terry Fox Foundation

    collaborator OTHER

  • Tata Memorial Hospital

    lead OTHER_GOV

Principal Investigators

  • Dr AJAY PURI, ORTHOPAEDIC ONCOLOGIST · Tata Memorial Hospital

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2010-06-30
Completion
2016-01-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05827458 on ClinicalTrials.gov